3 very different biotechs all file for the same IPO goal: A big raise on Nasdaq

A stem cell biotech, a liver disease specialist and a gene therapy company have all got in the conga line for the biotech IPO boom.

Phase 3 stem cell transplantation biotech Talaris Therapeutics (once known as Regenerex until a name change two years ago) wants $100 million, as too does U.K.-based biotech Gyroscope Therapeutics, while liver disease and cancer biotech Sagimet Biosciences wants a slightly more modest $75 million.